<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596804</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hA20-01EU</org_study_id>
    <nct_id>NCT00596804</nct_id>
  </id_info>
  <brief_title>Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to assess the safety and tolerance of different doses of humanized
      hA20 in patients with NHL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of hA20 with this administration schedule and dosing</measure>
    <time_frame>first 12 weeks, then over 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tolerance of hA20 with this administration schedule and dosing</measure>
    <time_frame>first 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>immunogenicity of hA20 with this administration schedule and dosing</measure>
    <time_frame>first 12 weeks, as needed over 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of hA20</measure>
    <time_frame>first 12 weeks, then up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics hA20</measure>
    <time_frame>first 12 weeks, then up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess efficacy</measure>
    <time_frame>4 and 12 weeks, then every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">39</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Lymphoma, Diffuse</condition>
  <condition>Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veltuzumab</intervention_name>
    <description>once weekly intravenous dosing for 4 weeks</description>
    <other_name>IMMU-106</other_name>
    <other_name>hA20</other_name>
    <other_name>humanized anti-CD20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, &gt;18 years old

          -  Histological diagnosis of CD20+ B-cell NHL (all grades) by WHO lymphoma criteria

          -  Failed at least one prior standard chemotherapy regimen for NHL

          -  Failed rituximab treatment for relapsed NHL

          -  Measurable NHL disease by CT, with at least one lesion &gt;1.5 cm in one dimension

          -  Adequate performance status (&gt;70 Karnofsky scale, 0-1 ECOG) with an estimated life
             expectancy of at least 6 months

          -  Adequate hematologic status, without ongoing transfusional support (hemoglobin ≥ 10
             g/dL, ANC ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L)

          -  Adequate renal and hepatic function, defined as: creatinine ≤ 1.5 x Institution Upper
             Limit of Normal (IULN), bilirubin ≤ 1.5 x IULN, AST and ALT ≤ 2.5 x IULN

          -  Otherwise, &lt;Grade 1 toxicity at study entry by NCI CTC version 2.0, including recovery
             from all acute toxicities incurred as a result of previous surgery, radiotherapy or
             chemotherapy, whether investigational or conventional.

          -  At least 6 months beyond previous rituximab treatment, 12 weeks beyond autologous stem
             cell transplant, 4 weeks beyond chemotherapy, other experimental treatments, or any
             radiation therapy to the index lesion(s).

          -  Ability to provide signed, informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women. Women of childbearing potential are required to have a
             negative pregnancy test

          -  Women of childbearing potential and fertile men who are not practicing or who are
             unwilling to practice birth control while enrolled in the study until at least 12
             weeks after the last weekly hA20 infusion.

          -  Rituximab resistant, defined as having progressed during or within 6 months of
             rituximab treatment.

          -  Excessive toxicity to rituximab (NCI CTC Grade 3 or 4) or known to be HACA positive

          -  Prior radioimmunotherapy, including Zevalin or Bexxar,

          -  Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested
             and negative

          -  Primary CNS lymphoma, HIV lymphoma or transformed lymphoma, or presence of symptomatic
             CNS metastases or carcinomatous meningitis.

          -  Bulky disease by CT, defined as any single mass &gt;10 cm in its greatest diameter

          -  Pleural effusion with positive cytology for lymphoma Known to be HIV positive, or
             hepatitis B or C positive

          -  Known autoimmune disease or presence of autoimmune phenomena.

          -  Evidence of infection or requiring antibiotics within 5 days.

          -  Corticosteroid use within 2 weeks

          -  Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma
             skin cancers and carcinoma in situ of the cervix.

          -  Other concurrent medical or psychiatric conditions that, in the Investigator's
             opinion, may be likely to confound study interpretation or prevent completion of
             studyprocedures and follow-up examinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Des Maladies Du Sang</name>
      <address>
        <city>Lille</city>
        <state>Cedex</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon</name>
      <address>
        <city>Lyon</city>
        <state>Pierre Benite Cedex</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 9HN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004 Apr 15;10(8):2868-78.</citation>
    <PMID>15102696</PMID>
  </reference>
  <reference>
    <citation>Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006 Oct 15;108(8):2736-44. Epub 2006 Jun 15.</citation>
    <PMID>16778139</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. doi: 10.3109/10428191003672123. Review.</citation>
    <PMID>20214444</PMID>
  </reference>
  <results_reference>
    <citation>Franck Morschhauser1*, John P Leonard2, Bertrand Coiffier3*, et.al. INITIAL SAFETY AND EFFICACY RESULTS OF A SECOND-GENERATION HUMANIZED ANTI-CD20 ANTIBODY, IMMU-106 (HA20), IN NON-HODGKINS LYMPHOMA: ASH abstract 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Morschhauser F, Leonard JP, Coiffier B Petillon M, Coleman M,. Bahkti A, Teoh N, Wegener WA, Goldenberg DM. Phase I/II result of a seoncd-generation humanized anti- CD20 antibody, IMMU-106 (.hA20), in NHL: 2006 ASCO Annual Meeting.Proceedings; 24/18S Part I of II:429s</citation>
  </results_reference>
  <results_reference>
    <citation>Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M, Coleman M,. Horne H, Teoh N, Wegener WA, Goldenberg DM. Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results. 2007 ASCO Annual Meeting.Proceedings; 25/18S Part I of II:449s</citation>
  </results_reference>
  <results_reference>
    <citation>Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. doi: 10.1200/JCO.2008.19.9117. Epub 2009 May 18.</citation>
    <PMID>19451441</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>follicular lymphoma</keyword>
  <keyword>B-cell lymphoma</keyword>
  <keyword>diffuse large cell lymphoma</keyword>
  <keyword>small lymphoctytic lymphoma</keyword>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>MALT</keyword>
  <keyword>marginal zone lymphoma</keyword>
  <keyword>High-Grade</keyword>
  <keyword>Intermediate-Grade</keyword>
  <keyword>Low-Grade</keyword>
  <keyword>Mixed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

